Skip to main content

Table 3 Patients with non-serious and serious ADRs in the total treated population (n = 463)

From: Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study

ADRs

n (%)

Patient events

 Patients with non-serious ADRs, totala

21 (4.5)

  OHSS

16 (3.5)

  Uterine polyp

2 (0.4)

  Progesterone increased

1 (0.2)

  Secondary hypothyroidism

1 (0.2)

  Tachycardia

1 (0.2)

  Blighted ovum

1 (0.2)

 Patients with serious ADRs, total

19 (4.1)

  Miscarriage

10 (2.2)

  OHSS

7 (1.5)

  Ectopic pregnancy

1 (0.2)

  Hyperemesis gravidarum

1 (0.2)

Babies born events

 Patients with non-serious ADRs, total

0

 Patients with serious ADRs, total

1 (0.2)

  Hypoplastic left heart syndrome

1 (0.2)

  1. ADR adverse drug reaction, OHSS ovarian hyperstimulation syndrome
  2. aOne patient experienced two non-serious ADRs (OHSS and uterine polyp)